---
title: "China's Impact Therapeutics seeks up to $117 million in Hong Kong IPO, term sheet shows"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/285136556.md"
datetime: "2026-05-05T00:16:21.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/285136556.md)
  - [en](https://longbridge.com/en/news/285136556.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/285136556.md)
---

# China's Impact Therapeutics seeks up to $117 million in Hong Kong IPO, term sheet shows

SINGAPORE, May 5 (Reuters) - Impact Therapeutics (7630.HK) , a Chinese cancer-drug developer, aims to raise up to $117 million in a Hong Kong initial public offering, according to a term sheet seen by Reuters on Tuesday.

-   Impact is offering 41.98 million shares at HK$19.75 to HK$21.75 ($2.52 to $2.78) each.
-   The deal could rise to $134 million if underwriters use an over-allotment option.
-   Six cornerstone investors, including Tencent (0700.HK) , will buy about $35.7 million of the stock.
-   Impact expects to price the IPO on May 11 and list on May 13. ($1 = 7.8329 Hong Kong dollars)

### Related Stocks

- [TCTZF.US](https://longbridge.com/en/quote/TCTZF.US.md)
- [TCEHY.US](https://longbridge.com/en/quote/TCEHY.US.md)
- [00700.HK](https://longbridge.com/en/quote/00700.HK.md)
- [80700.HK](https://longbridge.com/en/quote/80700.HK.md)
- [HTCD.SG](https://longbridge.com/en/quote/HTCD.SG.md)

## Related News & Research

- [Lingxing Seeks Hong Kong IPO, But Heavy Reliance On Aggregators Could Worry Investors](https://longbridge.com/en/news/284407061.md)
- [Faron AGM Backs Equity-Funding Flexibility and New Option Plan Amid Ongoing Losses](https://longbridge.com/en/news/285061189.md)
- [Switzerland's ADC Therapeutics beats Q1 revenue estimates](https://longbridge.com/en/news/285065301.md)
- [Where Roche Fits In A 2026 Portfolio](https://longbridge.com/en/news/284911193.md)
- [Evercore ISI Sticks to Their Buy Rating for Summit Therapeutics (SMMT)](https://longbridge.com/en/news/284912082.md)